Search Results
Jun 16, 2026, 00:00 ET METI-Supported Global South-Japan Tech Talent Internship Opens Applications for 2026 Program
Venture Support Co., Ltd.)Email address: [email protected]
More news about: DELOITTE TOHMATSU VENTURE SUPPORT CO., LTD.
Jun 16, 2026, 00:00 ET Estágio de Talentos Tecnológicos do Sul Global do Japão Apoiado pela METI abre inscrições para o Programa 2026
Support Co., Ltd.)Endereço de e-mail: [email protected]
More news about: DELOITTE TOHMATSU VENTURE SUPPORT CO., LTD.
Jun 16, 2026, 00:00 ET El programa de pasantías para talentos tecnológicos del Sur Global y Japón, respaldado por METI, abre el plazo de inscripción para la edición de 2026
Ltd.)Dirección de correo electrónico: [email protected]
More news about: DELOITTE TOHMATSU VENTURE SUPPORT CO., LTD.
Jun 16, 2026, 00:00 ET Le programme de stages « Global South-Japan Tech Talent », soutenu par le METI, ouvre les candidatures pour l'édition 2026
Support Co., Ltd.)Adresse e-mail : [email protected]
More news about: DELOITTE TOHMATSU VENTURE SUPPORT CO., LTD.
Jun 15, 2026, 17:58 ET 美納里尼集團於 2026 年歐洲血液學協會 (EHA) 年會公佈 Selinexor 聯合 Ruxolitinib 治療骨髓纖維化的第 3 期 SENTRY 試驗數據
兩組之間的差異未達統計學顯著水平，因此聯合治療組未能達到第二項共同主要終點。總存活期 (OS)：儘管於分析時相關數據尚未成熟，但與單獨接受 Ruxolitinib 治療相比，Selinexor 聯合治療已顯示出令人鼓舞的早期總存活期 (OS) 訊號。OS 為預先指定的次要終點之一。 研究顯示，接受 Selinexor 聯合治療的患者死亡風險降低超過 50% (HR 0.43)。脾臟體積縮小：在各個預先指定的亞組分析中，均觀察到一致的 SVR35 獲益。 值得注意的是，於第 24 週時，不論 Ruxolitinib 的劑量高低，包括每日接受少於 15 毫克 Ruxolitinib 治療的患者，Selinexor 聯合治療均能實現更優越的脾臟體積縮小效果。變異等位基因頻率
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 16:44 ET Le Groupe Menarini présente les résultats de l'essai clinique SENTRY de phase III sur l'association selinexor-ruxolitinib dans le traitement de la myélofibrose lors du congrès 2026 de l'Association européenne d'hématologie (EHA)
monothérapie. L'étude a montré une réduction de plus de 50 % du risque de décès chez les patients recevant le traitement combiné à base de selinexor (HR = 0,43).Réduction du volume de la rate : on a observé un bénéfice constant de la SVR35 dans tous les sous-groupes prédéfinis. Il convient
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 13:00 ET NuPlay Now Available in the Microsoft Marketplace
Nurix builds agentic AI that powers enterprise operations from customer support and sales to HR, IT, retail, and vendor management. Its agents autonomously resolve queries, execute workflows, and drive outcomes across voice, chat, email, and SMS.
More news about: NuPlay
Jun 15, 2026, 12:30 ET PrismHR Unveils Its AI-Powered Intelligence Layer, Prism Intelligence (Pi), and Embedded AI Assistant, Prisma, to Transform How Work Gets Done
(ASOs) and payroll service providers. PrismHR's technology supports HR, payroll, benefits, compliance, onboarding and employee experience for millions of worksite employees across the United States. Today, PrismHR powers a significant portion of the HR outsourcing industry, helping providers grow, operate efficiently, and
More news about: PrismHR
Jun 15, 2026, 09:15 ET Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio [HR] 0.479; 95% CI: 0.33, 0.68; P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the
More news about: Inhibrx Biosciences, Inc.
Jun 15, 2026, 09:00 ET Lightcast Named to TIME's Inaugural List of America's Top WorkTech Companies for 2026
notable for its emphasis on both business performance and market influence. Statista's analysis examined thousands of companies across categories including HR technology, workforce management, employee experience, learning and development, and workplace operations. The research combined multiple data sources
More news about: Lightcast
Jun 15, 2026, 09:00 ET AMN Healthcare Names New Chief Commercial Officer and Chief People Officer to Advance Growth and Culture
our market strategy, differentiate our client value proposition and create stronger alignment across the client lifecycle. Holly is a transformative HR leader with the experience and expertise to continue building a place where our team members can thrive and do their best work."As Chief Commercial
More news about: AMN Healthcare Services, Inc.
Jun 15, 2026, 08:01 ET ManpowerGroup Returns to VivaTech to Power the Shift from AI Ambition to Workforce Reality
models automation potential and efficiency gains over three years.Agents-to-Humans, a human-centered orchestration platform that automates HR processes while maintaining transparency, accountability, and human oversight.Beaulieu-James returns to the ManpowerGroup booth at
More news about: ManpowerGroup
Jun 15, 2026, 07:40 ET El Grupo Menarini presenta datos del ensayo de fase 3 SENTRY de selinexor más ruxolitinib en mielofibrosis
ruxolitinib solo. El estudio mostró una reducción superior al 50 % en el riesgo de muerte para los pacientes que recibieron la combinación de selinexor (HR 0,43).• Reducción del volumen del bazo: Se observó un beneficio constante de RVS35 en todos los subgrupos preespecificados. En particular,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 07:00 ET The Centre for Addiction and Mental Health Optimizes Operations and Patient Care with Oracle Fusion Cloud Applications
Oracle Health Electronic Health Record (EHR), CAMH is extending its Oracle footprint across finance, HR, supply chain, and customer experience to optimize business processes and support enterprise-wide operations.
More news about: Oracle
Jun 15, 2026, 07:00 ET Il Gruppo Menarini presenta i dati dello studio di fase 3 SENTRY su selinexor più ruxolitinib nella mielofibrosi in occasione del Congresso 2026 dell'Associazione Europea di Ematologia (EHA)
solo ruxolitinib. Lo studio ha mostrato una riduzione superiore al 50% del rischio di morte per i pazienti trattati con la combinazione di selinexor (HR 0,43).Riduzione del volume splenico: è stato osservato un beneficio costante in termini di SVR35 in tutti i sottogruppi prestabiliti.
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
regimens.The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which accounts for approximately 65% of all breast cancers, and triple-negative breast cancer (TNBC), which represents 10-20% of cases.
More news about: Akeso, Inc.
Jun 15, 2026, 02:15 ET SPJIMR's TPO Summit 2026 (Bengaluru edition) fosters dialogue on the future of campus recruitment
Talent Acquisition, APAC & India, Amadeus Software; Neha Srivastava, Senior VP – HR, MetricStream; Sipra Majumdar, Director – People & Culture, SiMa.ai; Sridevi NV, CPO, VTU; and Satender Sighadia, Head – HR, GPS Renewables.For more such news and updates from SPJIMR, visit our
More news about: S.P. Jain Institute of Management & Research (SPJIMR)
Jun 14, 2026, 13:13 ET Menarini Group reporta datos del ensayo SENTRY de fase 3 de Selinexor Plus Ruxolitinib en mielofibrosis en el Congreso de la Asociación Europea de Hematología (EHA) 2026
ruxolitinib solo. El estudio mostró una reducción superior al 50 % en el riesgo de muerte para los pacientes que recibieron la combinación de selinexor (HR 0,43).Reducción del volumen del bazo: se observó un beneficio consistente de SVR35 en todos los subgrupos preespecificados. En particular,
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:10 ET Grupo Menarini relata dados do Ensaio SENTRY de Fase 3 de Selinexor Plus Ruxolitinibe em mielofibrose no Congresso da Associação Europeia de Hematologia (EHA) 2026
comparação com ruxolitinibe sozinho. O estudo mostrou uma redução superior a 50% no risco de morte para os pacientes que receberam a combinação de selinexor (HR 0,43).Redução do volume do baço: O benefício consistente de SVR35 foi observado em subgrupos pré-especificados. Notavelmente, na semana
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 13:06 ET Die Menarini Group präsentiert auf dem Kongress der European Hematology Association (EHA) 2026 Daten aus der Phase-3-Studie SENTRY zur Kombination von Selinexor und Ruxolitinib bei Myelofibrose
sekundärer Endpunkt, beobachtet. Die Studie zeigte eine Reduktion des Sterberisikos um mehr als 50 % bei Patienten, die die Selinexor-Kombination erhielten (HR 0,43).Verringerung des Milzvolumens: Ein konsistenter SVR35-Nutzen wurde in allen vorab festgelegten Subgruppen beobachtet. Bemerkenswert
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 07:26 ET Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
combination compared to ruxolitinib alone. The study showed a greater than 50% reduction in the risk of death for patients receiving the selinexor combination (HR 0.43).Spleen Volume Reduction: Consistent SVR35 benefit was observed across prespecified subgroups. Notably, at week 24, superior spleen
More news about: Menarini Industrie Farmaceutiche Riunite
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
was not yet mature at this analysis (HR=0.89 [95% CI, 0.57-1.40]), and final testing of OS superiority is planned at a future date. An additional secondary endpoint, time to next treatment (TTNT), consistently favored the pirtobrutinib combination regimen (HR=0.50 [95% CI, 0.35-0.70]; nominal p<0.0001).The
More news about: Eli Lilly and Company
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
follow-up of two years (24.6 months), results showed significant improvement in PFS for Tal-DP (hazard ratio [HR], 0.28; 95 percent confidence interval [CI], 0.20-0.40; p<0.0001) and Tal-D (HR, 0.33; 95% CI, 0.24-0.46; p<0.0001). At 24 months, Tal-DP showed a PFS rate of 81.3% and Tal-D showed a PFS
More news about: Johnson & Johnson
Jun 12, 2026, 14:30 ET कार्यबल की जटिलता बढ़ने के साथ-साथ पेरोल रणनीतिक दृष्टि से महत्वपूर्ण हो गया है: ADP
एक रणनीतिक प्रवर्तक बन रहा है। यह परिवर्तन सटीकता और उत्तरदायित्व के साथ उच्च जोखिम वाले वेतन और HR प्रोसेसों की मैनेजमेंट के लिए विश्वसनीय भागीदारों की बढ़ती आवश्यकता को रेखांकित करता है।वरिष्ठ HR, वित्त तथा पेरोल अग्रणीयों से प्राप्त जानकारियों के आधार पर पूरे भारत की यह रिपोर्ट रेखांकित करती
More news about: ADP, Inc.
Jun 12, 2026, 13:06 ET Rutgers Business School ranks among top MBA programs in the U.S. for return on investment
heavily on cultivating AI talent and developing a strategy for adapting the technology in day-to-day work processes.Fils, who was employed in HR before starting her MBA, flirted with the idea of going into marketing, but returned to the human resources space. "The Rutgers MBA program allowed me
More news about: Rutgers Business School